Galera

Actithera Group

This company develops radioligand therapies to treat cancer patients by delivering radiation directly to solid tumours while sparing healthy tissue.

Actithera

This biotechnology company develops targeted radioligand therapies to treat cancer patients by delivering radioactive isotopes directly to solid tumours.

G1 Therapeutics

This company develops and commercialises small molecule therapies to protect bone marrow in cancer patients undergoing chemotherapy.

BiPER Therapeutics

This company develops small molecule drugs targeting the BiP protein to treat gastrointestinal cancers and other pathological conditions in humans.

Applied Biotherapeutics

This company develops platform technologies for delivering low-dose radiation precisely at tumor margins for cancer patients undergoing surgical removal.

Alpha-9 Theranostics

This clinical-stage biotechnology company develops targeted radiopharmaceuticals to treat cancer patients by delivering radiation directly to tumours while sparing healthy tissue.

Accent Therapeutics

This biopharmaceutical company develops small molecule precision therapies for patients with various types of cancer.

Galecto

This biotechnology company develops small molecule therapeutics targeting galectin-3 and LOXL2 to treat patients with fibrosis, inflammation and cancer.